Novartis’ Adakveo approved by FDA to reduce VOCs in sickle cell disease

Formerly known as SEG101, Adakveo has been approved for reducing the incidents of vaso-occlusive crises (VOCs), or pain crises, in adult patients with sickle cell disease, aged 16

The post Novartis’ Adakveo approved by FDA to reduce VOCs in sickle cell disease appeared first on Pharmaceutical Business review.